ABSTRACT
Investment, collaboration, and coordination have been key.
Subject(s)
Biomedical Research , COVID-19 , Humans , Biomedical Research/economics , Biomedical Research/trends , COVID-19/prevention & control , COVID-19/therapy , National Institutes of Health (U.S.) , Investments , International Cooperation , COVID-19 Vaccines , Clinical Trials as TopicSubject(s)
Coronavirus Infections/drug therapy , Coronavirus Infections/prevention & control , Intersectoral Collaboration , Pandemics/prevention & control , Pneumonia, Viral/drug therapy , Pneumonia, Viral/prevention & control , Viral Vaccines , Betacoronavirus , COVID-19 , COVID-19 Vaccines , Drug Industry , Humans , National Institutes of Health (U.S.) , SARS-CoV-2 , Time Factors , United States , United States Food and Drug Administration , COVID-19 Drug TreatmentABSTRACT
Ideally, an anti-HIV drug should (1) be highly active against wild-type and mutant HIV without allowing breakthrough; (2) have high oral bioavailability and long elimination half-life, allowing once-daily oral treatment at low doses; (3) have minimal adverse effects; and (4) be easy to synthesize and formulate. R278474, a new diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI), appears to meet these criteria and to be suitable for high compliance oral treatment of HIV-1 infection. The discovery of R278474 was the result of a coordinated multidisciplinary effort involving medicinal chemists, virologists, crystallographers, molecular modelers, toxicologists, analytical chemists, pharmacists, and many others.
